In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
As of close of business last night, Neumora Therapeutics Inc’s stock clocked out at $1.74, up 2.96% from its previous closing price of $1.69. In other words, the price has increased by $2.96 from its previous closing price. On the day, 1.19 million shares were traded. NMRA stock price reached its highest trading level at $1.795 during the session, while it also had its lowest trading level at $1.7.
Ratios:
To gain a deeper understanding of NMRA’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 10.98 and its Current Ratio is at 10.98. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, RBC Capital Mkts on January 02, 2025, Downgraded its rating to Sector Perform and sets its target price to $4 from $29 previously.
On November 05, 2024, JP Morgan Downgraded its rating to Neutral which previously was Overweight and also lowered its target price recommendation from $18 to $15.
On October 01, 2024, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $30.H.C. Wainwright initiated its Buy rating on October 01, 2024, with a $30 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Oct 18 ’24 when Fust Matthew K sold 14,049 shares for $17.03 per share. The transaction valued at 239,319 led to the insider holds 20,100 shares of the business.
Fust Matthew K sold 7,739 shares of NMRA for $131,643 on Oct 17 ’24. The Director now owns 20,100 shares after completing the transaction at $17.01 per share. On Oct 18 ’24, another insider, Fust Matthew K, who serves as the Director of the company, bought 14,049 shares for $17.03 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NMRA now has a Market Capitalization of 281116128 and an Enterprise Value of -57445748.
Stock Price History:
The Beta on a monthly basis for NMRA is 2.53, which has changed by -0.9056399 over the last 52 weeks, in comparison to a change of 0.22894537 over the same period for the S&P500. Over the past 52 weeks, NMRA has reached a high of $21.00, while it has fallen to a 52-week low of $1.60. The 50-Day Moving Average of the stock is -68.03%, while the 200-Day Moving Average is calculated to be -82.38%.
Shares Statistics:
It appears that NMRA traded 3.09M shares on average per day over the past three months and 1688910 shares per day over the past ten days. A total of 160.48M shares are outstanding, with a floating share count of 55.88M. Insiders hold about 65.86% of the company’s shares, while institutions hold 36.09% stake in the company. Shares short for NMRA as of 1738281600 were 10256517 with a Short Ratio of 3.32, compared to 1735603200 on 12989499. Therefore, it implies a Short% of Shares Outstanding of 10256517 and a Short% of Float of 12.01.
